Minute Insight: Thermo Fisher Gets FDA OK On Cancer Companion Diagnostic

The US FDA has approved additional indications for Thermo Fisher Scientific’s Oncomine Dx Target, allowing the companion diagnostic to be used to detect more varieties of lung and thyroid cancer.

Minute Insight
• Source: Informa/Alamy

The US Food and Drug Administration has granted its stamp of approval to Thermo Fisher Scientific’s Oncomine Dx Target for use in helping to identify patients who might benefit from treatment with Eli Lilly and Company drug Retevmo (selpercatinib).

The test identifies patients who have RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET-fusion positive advanced...

More from Minute Insights

More from Medtech Insight